Head-to-head · WeighScore
Hims & Hers vs Measured
The verdict
Hims & Hers takes it — 81/100 to 75.1/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hims & Hers | Measured |
|---|---|---|
| WeighScore | 81/100 | 75.1/100 |
| Grade | B− | C |
| Scorecard rank | #36 | #58 |
| Semaglutide | $199/mo | $119/mo (compounded) |
| Tirzepatide | Not disclosed | $219/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #36 · B−
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Graded #58 · C
Strengths
- Membership includes 1:1 nutrition support and board-certified provider care
- Both compounded (from $79/mo microdose, $119 semaglutide, $229 tirzepatide) and brand-name Wegovy/Zepbound
- Insurance or cash-pay options for brand-name medications
- Oral option available (Wegovy pill); cancel-anytime membership
Where it loses points
- The headline $79 'GLP-1 Microdose' is a promotional rate off a $99 list price, is filed by the provider under longevity rather than weight loss, and is not a labelled therapeutic dose of either molecule
- Branded plans are a $49/mo membership with the medication billed separately at $149 to $449/mo
- The site never states which billing term its 'from' prices assume, though the terms allow monthly, quarterly, semi-annual and annual
- No state count is published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.